Literature DB >> 30157754

Changes in gut microbiota and plasma inflammatory factors across the stages of colorectal tumorigenesis: a case-control study.

Yongzhen Zhang1,2, Xin Yu3, Enda Yu4, Na Wang3, Quancai Cai5, Qun Shuai1, Feihu Yan4, Lufang Jiang3, Hexing Wang3, Jianxiang Liu3, Yue Chen6, Zhaoshen Li7, Qingwu Jiang8.   

Abstract

BACKGROUND: Colorectal cancer (CRC) is a common malignant gastrointestinal tumor. In China, CRC is the 5th most commonly diagnosed cancer. The vast majority of CRC cases are sporadic and evolve with the adenoma-carcinoma sequence. There is mounting evidence indicating that gut microbiota and inflammation play important roles in the development of CRC although study results are not entirely consistent. In the current study, we investigated the changes in the CRC-associated bacteria and plasma inflammatory factors and their relationships based on data from a case-control study of Han Chinese. We included 130 initially diagnosed CRC patients, 88 advanced colorectal adenoma patients (A-CRA), 62 patients with benign intestinal polyps and 130 controls.
RESULTS: Fecal microbiota composition was obtained using 16S ribosomal DNA (16S rDNA) sequencing. PCOA analysis showed structural differences in microbiota among the four study groups (P = 0.001, Unweighted Unifrac). Twenty-four CRC-associated bacteria were selected by a two-step statistical method and significant correlations were observed within these microbes. CRC-associated bacteria were found to change with the degree of malignancy. Plasma C-reactive protein (CRP) and soluble tumor necrosis factor II (sTNFR-II) displayed significant differences among the four study groups and increased with adenoma-carcinoma sequence. The correlations of CRP and sTNFR-II with several CRC-associated microbes were also explored.
CONCLUSIONS: CRC-associated species and plasma inflammatory factors tended to change along the adenoma-carcinoma sequence. Several CRC-associated bacteria were correlated with CRP and sTNFR-II. It is likely that gut microbiome and inflammation gradually form a microenvironment that is associated with CRC development.

Entities:  

Keywords:  Colorectal cancer (CRC); Correlation analysis; Gut microbiota; Plasma inflammatory factors

Mesh:

Substances:

Year:  2018        PMID: 30157754      PMCID: PMC6114884          DOI: 10.1186/s12866-018-1232-6

Source DB:  PubMed          Journal:  BMC Microbiol        ISSN: 1471-2180            Impact factor:   3.605


Background

Colorectal cancer (CRC) is the third common cancer worldwide causing 1.4 million newly diagnosed cases and 694,000 deaths a year [1]. In China, CRC is the 5th most commonly diagnosed cancer for both males and females and the incidence rate has been rapidly increasing recently [2]. The development of CRC is regarded as a multifactorial process involving genes mutation accumulation, inflammation and lifestyle factors, such as dietary habits and smoking [3-6]. Gut microbiome and inflammation are hypothesized to shape the tumor microenvironment and promote the tumorigenesis [7-10]. Previous observational and experimental studies have identified and suspected several microbes as potential drivers of CRC, including Fusobacterium nucleatum, Streptococcus bovis/gallolyticus, enterotoxigenic B. fragilis (ETBF), Enterococcus faecalis and colibactin-producing Escherichia coli. In recent studies, more detailed microbial profiles gained by high-throughput analyses, like metagenomic shotgun-sequencing and 16S rDNA sequencing, have revealed more bacteria that are associated with CRC [11-13]. Pathogenic microbes may work with inflammatory factors in CRC progression [14]. The enrichment of S. bovis is associated with an increased expression of pro-inflammatory genes [15]. ETBF can activate the signal transducer and activator of transcription 3 (STAT3) and induce Th17 cell infiltration as well as cytokines releasing in the colon of ApcMin/+ mice [5]. F. nucleatum infection can increase the expression of proinflammatory genes such as Scyb1, Interleukin-6 (IL-6), tumor necrosis factor (TNF-α), and Mmp3 [16]. However, there is a lack of consistent results for the effects of plasma inflammatory factors on CRC development from population-based studies [14, 17–21]. The major course of sporadic CRC progression begins with aberrant crypts, advances with early and late adenomatous polyps and finally turns into invasive carcinoma [6]. However, the changes in CRC-associated bacteria and inflammatory factors across the adenoma-carcinoma sequence and the potential correlations between them have not been clarified. We conducted a case-control study, which included CRC patients, A-CRA patients, patients with benign polyps and controls, to examine the relationships among CRC-associated microbiota, inflammatory factors and colon cancer status.

Methods

Study population and sampling

A case-control study was carried out and participants were from outpatients who received the colonoscopy at Changhai Hospital in Shanghai in 2014-2015. Persons who were capable to complete a questionnaire interview and to provide relevant biological samples were eligible for study inclusion. Patient exclusion criteria included: (a) patients younger than 40 years of age, (b) persons not Han people, (c) patients with prior diagnoses of colorectal cancer, colorectal adenoma, inflammatory bowel disease (IBD) or other cancers, (d) patients had a family history of colorectal cancer in first- and second-degree relatives and no family history of neoplastic polyps or hereditary syndromes in first degree relatives under 60 years of age, and (e) patients had used antibiotics in last 6 months before colonoscopy. Hereditary syndromes include familial adenomatous polyposis (FAP), hereditary nonpolyposis colorectal cancer (HNPCC), Turcot syndrome, Oldfield syndrome and juvenile polyposis syndrome. Control selection was based on the same inclusion/exclusion criteria as used for case selection. All participants had not been diagnosed or screened positive for colorectal cancer before inclusion and had no diet restrictions. Controls were outpatients who had no CRC or polyps indicated by colonoscopy and had no specific symptoms of CRC and were frequently matched with CRC patients by gender and age. Polyethylene glycol lavage solution was used for bowel preparation. Colonoscopy was performed by experienced endoscopists using a standard video colonoscope (Olympus Optical Co, Tokyo, Japan). Written informed consents were acquired from all participants.

Sample collection and laboratory testing

Before the colonoscopy, fresh stool samples (≥1 g) were collected at the hospital in a unified large centrifuge tube and stored in the − 80 °C fridge instantly. The stool samples were frozen-thawed once before an extraction of DNA. Biopsy specimens were collected during colonoscopy. After the colonoscopy, a questionnaire interview was conducted to collect basic demographic information, medical history and lifestyle factors (including smoking and alcohol drinking). Participants provided 2 ml venous blood that was preserved in − 80 °C fridge instantly for corresponding laboratory assay. Blood samples were centrifuged at 3000 rpm for 10 min to separate plasma. Plasma soluble tumor necrosis factor receptor 2 (sTNFR-II) was measured as a surrogate for TNF-α. CRP, IL-6, and sTNFR-II in plasma were measured with ELISA method (human CRP ELISA Kit 96 T, Anogen; Human IL-6 ELISA Kit 96 T, Anogen; Human sTNFR-II ELISA Kit 96 T, Raybiotech) according to standard procedures provided by the manufacturers. Obesity/overweight status was assessed according to the criteria for Chinese adults (defines overweight as BMI ≥ 24 kg/m2 and obesity as BMI ≥ 28 kg/m2) [22]. For the patients, lesions located in the cecum, ascending colon, hepatic flexure, transverse colon and splenic flexure were considered as proximal lesions, and descending colon, sigmoid colon and rectum were deemed distal lesions [23].

DNA extraction and 16S rDNA sequencing

Bacterial genomic DNA was extracted from stool samples using OMEGA-soil DNA Kit (USA Omega Bio-Tek) and examined by 1% agarose gel electrophoresis. V3-V4 region of the 16S rDNA gene was amplified by universal primers (forward 338F 5’-ACTCCTACGGGAGGCAGCAG-3′ and reverse 806R 5’-GGACTACHVGGGTWTCTAAT-3′), while attaching Illumina adapters and sample-specific barcode sequences. The V3-V4 hypervariable region provides appropriate information for taxonomic classification of microbial analysis from specimens associated with human microbiome studies and was used by the Human Microbiome Project [24]. Polymerase chain reaction (PCR) was performed by ABI GeneAmp® 9700, with TransStart Fastpfu DNA Polymerase, 20 μl reaction systems. Each sample repeated the conduction for three times and PCR products, quantified by QuantiFluor™ -ST Fluorescence System (Promega), was pooled by AxyPrep DNA gel extraction kit (Axygen, USA) to prepare for sequencing. The Illumina MiSeq platform (Illumina, USA) was served in sequencing the amplicons.

Bioinformation analysis and statistical analysis

Paired-end reads were merged into one sequence in terms of overlapping (FLASH) and split by barcodes and primers. Reads with low quality and adaptors were removed (Trimmomatic 0.27). Dereplicated sequences (without singletons) were clustered into operational taxonomic units (OTUs), with 97% similarity. Representative sequences were picked out and classified by SINTAX (USEARCH v.10) algorithm using the RDP training set v16 with species names at a confidence threshold of 0.8 for genus and of 0.5 for species [25]. Alpha-diversity and the β-diversity of the microbiota data were computed using QIIME v.1.9.1 to assess the diversity alteration of microbiome [26]. Alpha-diversity measurements included ace, shannon index, simpson and PD whole tree. β-diversity was measured by unweighted and weighted UniFrac distances between samples considered phylogenetic information. To assess overall fecal microbiota composition discrepancies, Permutational Multivariate Analysis of Variance Using Distance Matrices (PMANOVA) was performed based on the UniFrac distances, and potential confounders (gender, age, BMI, smoking and drinking status) were taken into consideration. Principal Coordinates Analysis (PCoA) was applied to visualize similarities or dissimilarities of the microbiota of samples in different groups using the β-diversity distances mentioned previously. CRC-associated microbes were selected by two steps. Firstly, species were applied the Zero-inflated Log-Normal mixture model in the metagenomeSeq packages and microbes with adjusted P values less than 0.05 were selected [27]. Secondly, selected microbiota was further filtered by the random forest algorithm in the Boruta package with 1000 iterations [28]. Selected species were clustered by a hierarchical ward-linkage method with Spearman correlation. P values of multiple comparisons or correlations tests were adjusted using the Benjamini-Hochberg method. Pearson χ2 test or Fisher’s exact test was applied to analyze qualitative clinical information of patients if appropriate. One-way ANOVA followed by Tukey HSD test was used to analyze the differences in age and α-diversity among the four study groups. Kruskal-Wallis test and Dunn’s test post-hoc method was applied to assess the differences in inflammatory factors. Jonckheere-Terpstra test was used to investigate the trend for inflammatory factors and CRC-associated bacteria along with the adenoma-carcinoma sequence. Correlation networks based on Spearman’s rank correlations were performed to visualize the associations between serum factors and gut microbiota by Cytoscape 3.6.1. Statistical analyses were carried out in R v 3.4.4.

Results

Demographic and clinical information

A total of 130 CRC patients, 88 A-CRA patients, 32 patients with colorectal adenoma, 30 patients with hyperplastic polyps and 130 controls were included in our study. We combined the colorectal adenoma patients and patients with hyperplastic polyps into one group (“polyps group”). The selection of participants and collection of specimens are summarized in Fig. 1.
Fig. 1

Flowchart for the selection of participants and collection of specimens. Gender, BMI and chronic diseases (heart disease, hypertension, and diabetes) showed no significant differences among the four study groups. Mean (SD) age of all participants was 59.1 (9.6) years. The included patients in the polyps group were younger than those with CRC (P = 0.033). The proportion of smoking in CRC (P = 0.044) and A-CRA (P = 0.002) patients was higher than controls. There were more patients with distal lesions than those with proximal lesions (Table 1). Among the CRC patients, 20.7%, 42.3% and 36.2% were in the TNM stages I, II and III, respectively

Flowchart for the selection of participants and collection of specimens. Gender, BMI and chronic diseases (heart disease, hypertension, and diabetes) showed no significant differences among the four study groups. Mean (SD) age of all participants was 59.1 (9.6) years. The included patients in the polyps group were younger than those with CRC (P = 0.033). The proportion of smoking in CRC (P = 0.044) and A-CRA (P = 0.002) patients was higher than controls. There were more patients with distal lesions than those with proximal lesions (Table 1). Among the CRC patients, 20.7%, 42.3% and 36.2% were in the TNM stages I, II and III, respectively
Table 1

Demographic and clinical characteristics of patients and controls

CRC (n = 130)A-CRA (n = 88)polyps (n = 62)controls (n = 130)P Value
Gender
 Male65 (50.0%)55 (62.5%)31 (50.0%)65 (50.0%)0.228
 Female65 (50.0%)33 (37.5%)31 (50.0%)65 (50.0%)
Age(years)a60.5 (9.8)59.6 (10.3)56.5 (8.9)58.6 (8.9)0.045
BMI (kg/m2)
  < 24.069 (53.1%)44 (50.0%)30 (48.4%)74 (56.9%)0.299
 24.0-27.951 (39.2%)34 (38.6%)20 (32.3%)43 (33.1%)
  ≥ 28.010 (7.7%)10 (11.4%)12 (19.4%)13 (10.0%)
Alcohol drinking
 Never98 (75.4%)61 (69.3%)50 (80.6%)109 (83.8%)0.069
 Ever32 (24.6%)27 (30.7%)12 (19.4%)21 (16.2%)
Smoking
 Never91 (70.0%)54 (61.4%)42 (67.7%)105 (80.8%)0.015
 Ever39 (30.0%)34 (38.6%)20 (32.3%)25 (19.2%)
Lesion location
 Proximal45 (34.6%)27 (30.7%)30 (48.4%)0.072
 Distal85 (65.4%)61 (69.3%)32 (51.6%)
Hypertension
 No89 (68.5%)58 (65.9%)45 (72.6%)88 (67.7%)0.854
 Yes41 (31.5%)30 (34.1%)17 (27.4%)42 (32.3%)
Heart Disease
 No122 (93.8%)83 (94.3%)59 (95.2%)128 (98.5%)0.223
 Yes8 (6.2%)5 (5.7%)3 (4.8%)2 (1.5%)
Diabetes
 No117 (90.0%)80 (90.9%)59 (95.2%)120 (92.3%)0.658
 Yes13 (10.0%)8 (9.1%)3 (4.8%)10 (7.7%)

aAge was shown as mean (SD). BMI Body mass index

Demographic and clinical characteristics of patients and controls aAge was shown as mean (SD). BMI Body mass index

Stool microbiota sequencing results

A total of 28,800,738 high-quality reads were obtained from 410 samples (mean = 70,245.7). We subsampled 29,719 reads for each participant according to the sample with the least sequences. An OTU table with 1794 OTUs was constructed based on these sequences. Among the OTUs, 7 phyla, 22 classes, 34 orders, 70 families, 163 genera and 285 species were assigned (inclusive conditions: phylum > 0.1%, class to species > 0.001%). PCoA based on unweighted Unifrac distances showed a significant difference in gut microbiota among the four study groups (P = 0.001 for unweighted Unifrac distances; P = 0.320 for weighted Unifrac distances, PMANOVA, controlling for gender, age, BMI and status of smoking and drinking, Additional file 1: Figure S1). Alpha-diversity showed no significant difference among the four groups (ace: P = 0.153, shannon: P = 0.983; simpson: P = 0.814; PD whole tree: P = 0.08).

CRC-associated microbiota in CRC patients compared with controls

CRC-associated microbiota at the species level was selected. A total of 24 species were identified and filtered by the Zero-inflated Log-Normal mixture model and random forest algorithm. The CRC-associated species were divided into two clusters according to the hierarchical ward-linkage clustering in all 410 participants (Fig. 2). Pairwise correlations displayed in Fig. 3 showed that species within the cluster were positively related. Fourteen of 24 species increased in CRC patients including Peptostreptococcus stomatis, Parvimonas micra, Gemella morbillorum, Dialister pneumosintes, Porphyromonas asaccharolytica, Solobacterium moorei, Eisenbergiella tayi, Fusobacterium nucleatum, Ruminococcus torques, Eggerthella lenta, Clostridium symbiosum, Campylobacter rectus, Clostridium scindens, Clostridium lactatifermentans. The other 10 species including Eubacterium eligens, Coprococcus comes, Eubacterium hadrum, Eubacterium hallII, Fusicatenibacter saccharivorans, Blautia faecis, Roseburia faecis, Ruminococcus lactaris, Eubacterium desmolans, Streptococcus salivarius, decreased in CRC patients (Additional file 2: Table S1).
Fig. 2

Hierarchical ward-linkage clustering of CRC-associated species. Red labels represent for microbes increased in CRC patients while blue for decreased. The clustering was based on Spearman’s correlations among the four study groups

Fig. 3

Correlation plot of CRC-associated microbiota in CRC patients compared with controls. Correlations with an adjusted P value less than 0.05 were displayed

Hierarchical ward-linkage clustering of CRC-associated species. Red labels represent for microbes increased in CRC patients while blue for decreased. The clustering was based on Spearman’s correlations among the four study groups Correlation plot of CRC-associated microbiota in CRC patients compared with controls. Correlations with an adjusted P value less than 0.05 were displayed

Results of inflammatory factors in plasma

CRP and sTNFR-II levels were significantly different in the four study groups. We discovered that the level of plasma CRP in CRC patients was higher compared with the A-CRA group (P < 0.001) and the control group (P = 0.002). The CRP level in the polyps group was higher than controls (P = 0.031). The plasma sTNFR-II in the CRC group (P < 0.001) and the A-CRA group (P = 0.001) was higher compared with controls.

Trend analyses of CRC-associated bacteria and inflammatory factors

We analyzed the evolution of CRC-associated microbiota as the disease progressed. The results showed that all 24 species changed with the order of control-polyps-A-CRA-CRC, but no trend was found with the TNM stage (Additional file 2: Table S1). We also observed that CRP and sTNFR-II increased with the adenoma-carcinoma sequence (Fig. 4, CRP: JT = 36,401.5, P < 0.001, sTNFR-II: JT = 37,225.5, P < 0.001).
Fig. 4

Differences in plasma inflammatory factors among study groups. ** P < 0.01, * P < 0.05. Kruskal-Wallis tests followed with Dunn’s test post-hoc method. All values are expressed as median ± IQR

Differences in plasma inflammatory factors among study groups. ** P < 0.01, * P < 0.05. Kruskal-Wallis tests followed with Dunn’s test post-hoc method. All values are expressed as median ± IQR

Network analysis of CRC-associated microbiota and plasma inflammatory factors

Data from all the participants were used to analyze the correlations between the CRC-associated microbiota and inflammatory factors (Fig. 5). CRP, IL-6, and sTNFR-II were positively correlated with each other. Seven CRC-associated bacteria that increased in CRC patients including F. nucleatum, P. micra, P. stomatis, G. morbillorum, D. pneumosintes, S. moorei and C. retus displayed positive correlations with CRP. D. pneumosintes, F. nucleatum and P. stomatis showed positive correlations with sTNFR-II. Species including E. eligens, E. hadrum and R. faecis, which decreased in CRC patients, showed negative correlations with CRP. E. eligens was also negatively correlated with sTNFR-II (Additional file 3: Table S2).
Fig. 5

Correlation network among plasma inflammatory factors and CRC-associated species. The width of each edge corresponds to the absolute values of Spearman correlation coefficients and the transparency of edge represents an adjusted P value. The line color indicates the direction of a correlation (red for positive and blue for negative). The relative size of the node was determined by the relative abundance of the microbe. Correlations with an adjusted P value less than 0.05 were displayed

Correlation network among plasma inflammatory factors and CRC-associated species. The width of each edge corresponds to the absolute values of Spearman correlation coefficients and the transparency of edge represents an adjusted P value. The line color indicates the direction of a correlation (red for positive and blue for negative). The relative size of the node was determined by the relative abundance of the microbe. Correlations with an adjusted P value less than 0.05 were displayed

Discussion

In this case-control study, we identified CRC-associated microbes in CRC patients compared with controls and divided them into two clusters according to the Spearman correlation. Among all the 410 samples from patients and controls, CRC-associated microbes and plasma inflammatory factors changed with the colorectal adenoma-carcinoma sequence. The inflammatory factors were positively correlated with CRC-associated microbes that increased in CRC patients and negatively correlated with those that decreased in CRC patients. Our results support a previous hypothesis concerning the potent effect of oral periodontopathic bacteria in CRC carcinogenesis [29-31]. As expected, F. nucleatum was significantly enriched in CRC patients, which has been discussed widely in previous studies [16, 32, 33]. We also observed increased contributions of periodontal pathogens like P. micra, P. stomatis, P. oris, D. pneumosintes. and C. rectus [34-37]. The increased abundance of G. morbillorum was also observed. G. morbillorum is related with endodontic infections [38]. Flynn and his colleagues suggested a polymicrobial synergy hypothesis for the effect of oral pathogens in CRC tumorigenesis [29]. In the periodontitis, after invasive bacteria like F. nucleatum disrupt the epithelial barrier, metabolites are produced to change the microenvironment and promote inflammation for latter colonized microbiota like Porphyromonas spp. and Parvimonas spp. These pathogens can produce harmful factors that interfere with signal pathways, alter the permeability and promote periodontitis by releasing peptides and proteins. A similar mechanism may exist for oral pathogens in the colorectal tumorigenesis. We also observed co-abundance circumstance of these potential pathogens, further suggesting the possibility that they could work mutually in the development of CRC. Mounting evidence has shown that short-chain fatty acids (SCFAs) acetate, propionate, and butyrate function as suppressors of inflammation and tumorigenesis [5, 39]. The anaerobic microbes inhabited in the large intestine can ferment the undigested dietary components to produce SCFAs. SCFAs can take anti-inflammatory and anti-apoptotic effects by the mechanism including inhibiting histone deacetylase (HDAC) activity [39, 40]. Reducing the expression of inflammatory factors by butyrate via inhibiting the activation of the NF-κB can lead to an anti-inflammatory effect and interfere pre- cancerous cells in the early stage of CRC development [41]. The relationship between changes in SCFAs-producing microbiota and CRC is elucidated in previous studies [31, 42, 43]. Consistent with this notion, our data showed that the relevant abundance of E. hall II, E. hadrum, E. desmolans, R. faecis and C. comes were depleted, which are butyrate-producing bacteria [44-46]. The commensal bacterium with anti-inflammatory property S. salivarius also decreased in CRC patients. As part of the intestinal commensal flora, the reduction in SCFA-producing bacteria may be caused by an increase in other pathogenic microorganisms such as F. nucleatum. It is also supported by our observation of negative correlations between potential pathogens and these commensal microbes. It is widely accepted that most CRC cases are preceded by dysplastic adenomas, and dysplastic adenomas can progress into malignant forms following the adenoma-carcinoma sequence [47, 48]. Previous researches revealed that CRC-associated microbes altered along with the adenoma-carcinoma sequence and suggested the fecal microbiota might be useful in the early diagnosis and treatment of CRC [12, 13]. Consistent with previous studies, in the current study, the potential pathogens and SCFA-producing bacteria tended to increase or decrease with the degree of malignancy, which implied that CRC-associated microbes play an important role in the gradual formation of the tumor microenvironment. TNF-α and IL-6 are core cytokines in the colorectal tumor promotion by activating NF-κB signaling pathways and STAT3 [5, 49, 50]. CRP can be produced by hepatocytes in response to the IL-6 activated by immune cells [11] and can also enhance resistance to apoptosis via STAT3 and NF-κB pathway [51-53]. Experimental studies have revealed that inflammatory factors play an important role in the relationship between pathogens like F. nucleatum and CRC [20, 54]. Elevation of related gene expression and activation of pathways are also observed in CRC patients [11, 55]. However, previous population-based studies did not support inflammatory factors (IL-6, CRP, and TNF-α) to be adequate biomarkers for CRC [14, 17]. In our study, CRP and sTNFR-II tended to increase along the adenoma-carcinoma sequence. It is intriguing that, among all the participants, CRP and sTNFR-II were significantly correlated with several CRC-associated microbes. However, no significant difference was observed in IL-6 among the four study groups and no association was observed between plasma IL-6 and bacteria. The level of IL-6 in plasma is also influenced by adiposity and inflammation of other tissues which might be the reason for the inconsistency with CRP and sTNFR-II [14]. Further human and experimental research is warranted to confirm this relationship and disentangle the complex role of immune response in CRC. To our knowledge, this is the first case-control study to explore the associations of plasma inflammatory factors with CRC-associated microbiota. The enrolled patients were unaware of their disease status at the time of sampling and stool samples were obtained before colonoscopy, which avoided potential impacts of lifestyle and dietary changes. Strict operations conducted within one hospital reduced potential diagnostic biases. There were some limitations in our study. Only stool samples rather than mucosal specimen were used to study the profiles of the gut microbiome. Stool samples are considered to be only partially uniform with those of the mucosal microbiota [11, 56]. Repeated measurements and external validation could improve the stability and credibility of data but were not conducted in the current study. In addition, we chose 16S rDNA amplicon sequencing considering the cost and sample size, which is less accurate compared with the shotgun sequencing method, especially at the species level.

Conclusions

The current study investigated CRC-associated microbiota and their correlations with inflammatory factors. These bacteria, as well as plasma CRP and sTNFR-II, changed along the adenoma-carcinoma sequence. Several microbes were significantly correlated with CRP and sTNFR-II. Our study results support the note that gut microbiome and inflammation may gradually form a microenvironment to promote the development of CRC. Figure S1. PCOA analysis based on unweighted and weighted Unifrac distances. Figure S1A and B are PCOA results based on the unweighted Unifrac distance. Figure S1C and D are PCOA results based on the weighted Unifrac distance. (TIF 4739 kb) Table S1. The mean relative abundance, statistical parameter and trend analysis of CRC-associated microbes. (DOCX 20 kb) Table S2. Correlations among CRC-associated microbes and plasma inflammatory factors. (DOCX 31 kb)
  54 in total

Review 1.  Emerging cytokine networks in colorectal cancer.

Authors:  Nathan R West; Sarah McCuaig; Fanny Franchini; Fiona Powrie
Journal:  Nat Rev Immunol       Date:  2015-09-11       Impact factor: 53.106

Review 2.  The gut microbiota, bacterial metabolites and colorectal cancer.

Authors:  Petra Louis; Georgina L Hold; Harry J Flint
Journal:  Nat Rev Microbiol       Date:  2014-09-08       Impact factor: 60.633

3.  Gut microbiome development along the colorectal adenoma-carcinoma sequence.

Authors:  Qiang Feng; Suisha Liang; Huijue Jia; Andreas Stadlmayr; Longqing Tang; Zhou Lan; Dongya Zhang; Huihua Xia; Xiaoying Xu; Zhuye Jie; Lili Su; Xiaoping Li; Xin Li; Junhua Li; Liang Xiao; Ursula Huber-Schönauer; David Niederseer; Xun Xu; Jumana Yousuf Al-Aama; Huanming Yang; Jian Wang; Karsten Kristiansen; Manimozhiyan Arumugam; Herbert Tilg; Christian Datz; Jun Wang
Journal:  Nat Commun       Date:  2015-03-11       Impact factor: 14.919

Review 4.  A review of the potential mechanisms for the lowering of colorectal oncogenesis by butyrate.

Authors:  Kim Y C Fung; Leah Cosgrove; Trevor Lockett; Richard Head; David L Topping
Journal:  Br J Nutr       Date:  2012-06-07       Impact factor: 3.718

Review 5.  The colorectal adenoma-carcinoma sequence.

Authors:  A Leslie; F A Carey; N R Pratt; R J C Steele
Journal:  Br J Surg       Date:  2002-07       Impact factor: 6.939

Review 6.  Colorectal cancer.

Authors:  Hermann Brenner; Matthias Kloor; Christian Peter Pox
Journal:  Lancet       Date:  2013-11-11       Impact factor: 79.321

7.  Cancer incidence and mortality worldwide: sources, methods and major patterns in GLOBOCAN 2012.

Authors:  Jacques Ferlay; Isabelle Soerjomataram; Rajesh Dikshit; Sultan Eser; Colin Mathers; Marise Rebelo; Donald Maxwell Parkin; David Forman; Freddie Bray
Journal:  Int J Cancer       Date:  2014-10-09       Impact factor: 7.396

8.  Gut mucosal microbiome across stages of colorectal carcinogenesis.

Authors:  Geicho Nakatsu; Xiangchun Li; Haokui Zhou; Jianqiu Sheng; Sunny Hei Wong; William Ka Kai Wu; Siew Chien Ng; Ho Tsoi; Yujuan Dong; Ning Zhang; Yuqi He; Qian Kang; Lei Cao; Kunning Wang; Jingwan Zhang; Qiaoyi Liang; Jun Yu; Joseph J Y Sung
Journal:  Nat Commun       Date:  2015-10-30       Impact factor: 14.919

9.  Potential of fecal microbiota for early-stage detection of colorectal cancer.

Authors:  Georg Zeller; Julien Tap; Anita Y Voigt; Shinichi Sunagawa; Jens Roat Kultima; Paul I Costea; Aurélien Amiot; Jürgen Böhm; Francesco Brunetti; Nina Habermann; Rajna Hercog; Moritz Koch; Alain Luciani; Daniel R Mende; Martin A Schneider; Petra Schrotz-King; Christophe Tournigand; Jeanne Tran Van Nhieu; Takuji Yamada; Jürgen Zimmermann; Vladimir Benes; Matthias Kloor; Cornelia M Ulrich; Magnus von Knebel Doeberitz; Iradj Sobhani; Peer Bork
Journal:  Mol Syst Biol       Date:  2014-11-28       Impact factor: 11.429

10.  Serum Endotoxins and Flagellin and Risk of Colorectal Cancer in the European Prospective Investigation into Cancer and Nutrition (EPIC) Cohort.

Authors:  So Yeon Kong; Hao Quang Tran; Andrew T Gewirtz; Gail McKeown-Eyssen; Veronika Fedirko; Isabelle Romieu; Anne Tjønneland; Anja Olsen; Kim Overvad; Marie-Christine Boutron-Ruault; Nadia Bastide; Aurélie Affret; Tilman Kühn; Rudolf Kaaks; Heiner Boeing; Krasimira Aleksandrova; Antonia Trichopoulou; Maria Kritikou; Effie Vasilopoulou; Domenico Palli; Vittorio Krogh; Amalia Mattiello; Rosario Tumino; Alessio Naccarati; H B Bueno-de-Mesquita; Petra H Peeters; Elisabete Weiderpass; J Ramón Quirós; Núria Sala; María-José Sánchez; José María Huerta Castaño; Aurelio Barricarte; Miren Dorronsoro; Mårten Werner; Nicholas J Wareham; Kay-Tee Khaw; Kathryn E Bradbury; Heinz Freisling; Faidra Stavropoulou; Pietro Ferrari; Marc J Gunter; Amanda J Cross; Elio Riboli; W Robert Bruce; Mazda Jenab
Journal:  Cancer Epidemiol Biomarkers Prev       Date:  2016-01-11       Impact factor: 4.254

View more
  22 in total

1.  Inflammatory potential of diet and colorectal carcinogenesis: a prospective longitudinal cohort.

Authors:  Zhuyue Li; Kang Wang; Nitin Shivappa; James R Hébert; Hong Chen; Hui Liu; Xiaolian Jiang
Journal:  Br J Cancer       Date:  2022-02-08       Impact factor: 9.075

2.  Pro-inflammatory cytokine polymorphisms in ONECUT2 and HNF4A and primary colorectal carcinoma: a post genome-wide gene-lifestyle interaction study.

Authors:  Su Yon Jung; Jeanette C Papp; Eric M Sobel; Matteo Pellegrini; Herbert Yu; Zuo-Feng Zhang
Journal:  Am J Cancer Res       Date:  2020-09-01       Impact factor: 6.166

3.  Genetically determined elevated C-reactive protein associated with primary colorectal cancer risk: Mendelian randomization with lifestyle interactions.

Authors:  Su Yon Jung; Herbert Yu; Matteo Pellegrini; Jeanette C Papp; Eric M Sobel; Zuo-Feng Zhang
Journal:  Am J Cancer Res       Date:  2021-04-15       Impact factor: 6.166

4.  Metagenomic Analysis of Common Intestinal Diseases Reveals Relationships among Microbial Signatures and Powers Multidisease Diagnostic Models.

Authors:  Puzi Jiang; Sicheng Wu; Qibin Luo; Xing-Ming Zhao; Wei-Hua Chen
Journal:  mSystems       Date:  2021-05-04       Impact factor: 6.496

5.  Immune senescence and immune activation in elderly colorectal cancer patients.

Authors:  Silvia Giunco; Maria Raffaella Petrara; Francesca Bergamo; Paola Del Bianco; Marisa Zanchetta; Francesco Carmona; Vittorina Zagonel; Anita De Rossi; Sara Lonardi
Journal:  Aging (Albany NY)       Date:  2019-06-13       Impact factor: 5.682

6.  Leveraging Fecal Bacterial Survey Data to Predict Colorectal Tumors.

Authors:  Bangzhou Zhang; Shuangbin Xu; Wei Xu; Qiongyun Chen; Zhangran Chen; Changsheng Yan; Yanyun Fan; Huangkai Zhang; Qi Liu; Jie Yang; Jinfeng Yang; Chuanxing Xiao; Hongzhi Xu; Jianlin Ren
Journal:  Front Genet       Date:  2019-05-28       Impact factor: 4.599

Review 7.  Gut Bacteria and their Metabolites: Which One Is the Defendant for Colorectal Cancer?

Authors:  Samira Tarashi; Seyed Davar Siadat; Sara Ahmadi Badi; Mohammadreza Zali; Roberto Biassoni; Mirco Ponzoni; Arfa Moshiri
Journal:  Microorganisms       Date:  2019-11-13

Review 8.  Role of Gut Microbiota and Probiotics in Colorectal Cancer: Onset and Progression.

Authors:  Edgar Torres-Maravilla; Anne-Sophie Boucard; Amir Hossein Mohseni; Sedigheh Taghinezhad-S; Naima G Cortes-Perez; Luis G Bermúdez-Humarán
Journal:  Microorganisms       Date:  2021-05-10

Review 9.  Colorectal cancer: The epigenetic role of microbiome.

Authors:  Hussein Sabit; Emre Cevik; Huseyin Tombuloglu
Journal:  World J Clin Cases       Date:  2019-11-26       Impact factor: 1.337

Review 10.  Gut microbiota alterations are distinct for primary colorectal cancer and hepatocellular carcinoma.

Authors:  Wei Jia; Cynthia Rajani; Hongxi Xu; Xiaojiao Zheng
Journal:  Protein Cell       Date:  2020-08-14       Impact factor: 14.870

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.